COUSIN, Sophie; TOULMONDE, Maud; KIND, Michele; GUEGAN, Jean-Philippe; BESSEDE, Alban; CANTAREL, Coralie; BELLERA, Carine; ITALIANO, Antoine

doi:10.1186/s40164-022-00338-2

Langue

Article de revue

Ce document a été publié dans

Experimental Hematology & Oncology. 2022-12-06, vol. 11, n° 1

Résumé en anglais

Breast cancer is one the most common cause of cancer death in women worldwide. We report here the first phase II study investigating a virus genetically engineered for tumor-selective replication in patients with breast cancer. Ten patients were treated with a combination of low-dose oral cyclophosphamide and intra-venous JX-594, a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) and β-galactosidase. Best response as per RECIST criteria was stable disease for 2 patients and progressive disease for 8 patients. Median progression-free and overall survival were 1.6 months (95% CI: [1.1-1.9]) and 14.4 months (95% CI: [2.0 - NA]) respectively. High throughput analysis of sequential plasma samples revealed an upregulation of protein biomarkers reflecting immune induction such as IFN gamma. Whether the combination of JX-594 with an immune checkpoint inhibitor is associated with meaningful clinical activity is therefore worth to investigate.< Réduire

Mots clés en anglais

Breast cancer

Oncolytic virus

JX-594

URI

https://oskar-bordeaux.fr/handle/20.500.12278/171952

DOI

http://dx.doi.org/10.1186/s40164-022-00338-2

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche